Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 16

1.

Neoantigen Dissimilarity to the Self-Proteome Predicts Immunogenicity and Response to Immune Checkpoint Blockade.

Richman LP, Vonderheide RH, Rech AJ.

Cell Syst. 2019 Oct 8. pii: S2405-4712(19)30307-2. doi: 10.1016/j.cels.2019.08.009. [Epub ahead of print]

PMID:
31606370
2.

Tumor cell-intrinsic EPHA2 suppresses anti-tumor immunity by regulating PTGS2 (COX-2).

Markosyan N, Li J, Sun YH, Richman LP, Lin JH, Yan F, Quinones L, Sela Y, Yamazoe T, Gordon N, Tobias JW, Byrne KT, Rech AJ, FitzGerald GA, Stanger BZ, Vonderheide RH.

J Clin Invest. 2019 Jun 4;130:3594-3609. doi: 10.1172/JCI127755.

3.

Genomic Signatures Predict the Immunogenicity of BRCA-Deficient Breast Cancer.

Kraya AA, Maxwell KN, Wubbenhorst B, Wenz BM, Pluta J, Rech AJ, Dorfman LM, Lunceford N, Barrett A, Mitra N, Morrissette JJD, Feldman M, Nayak A, Domchek SM, Vonderheide RH, Nathanson KL.

Clin Cancer Res. 2019 Jul 15;25(14):4363-4374. doi: 10.1158/1078-0432.CCR-18-0468. Epub 2019 Mar 26.

PMID:
30914433
4.

Tumor Cell-Intrinsic Factors Underlie Heterogeneity of Immune Cell Infiltration and Response to Immunotherapy.

Li J, Byrne KT, Yan F, Yamazoe T, Chen Z, Baslan T, Richman LP, Lin JH, Sun YH, Rech AJ, Balli D, Hay CA, Sela Y, Merrell AJ, Liudahl SM, Gordon N, Norgard RJ, Yuan S, Yu S, Chao T, Ye S, Eisinger-Mathason TSK, Faryabi RB, Tobias JW, Lowe SW, Coussens LM, Wherry EJ, Vonderheide RH, Stanger BZ.

Immunity. 2018 Jul 17;49(1):178-193.e7. doi: 10.1016/j.immuni.2018.06.006. Epub 2018 Jun 26.

5.

Radiotherapy and CD40 Activation Separately Augment Immunity to Checkpoint Blockade in Cancer.

Rech AJ, Dada H, Kotzin JJ, Henao-Mejia J, Minn AJ, Twyman-Saint Victor C, Vonderheide RH.

Cancer Res. 2018 Aug 1;78(15):4282-4291. doi: 10.1158/0008-5472.CAN-17-3821. Epub 2018 May 29.

6.

Tumor Immunity and Survival as a Function of Alternative Neopeptides in Human Cancer.

Rech AJ, Balli D, Mantero A, Ishwaran H, Nathanson KL, Stanger BZ, Vonderheide RH.

Cancer Immunol Res. 2018 Mar;6(3):276-287. doi: 10.1158/2326-6066.CIR-17-0559. Epub 2018 Jan 16.

7.

T-Cell Transfer Therapy Targeting Mutant KRAS.

Rech AJ, Vonderheide RH.

N Engl J Med. 2017 Feb 16;376(7):e11. No abstract available.

PMID:
28207208
8.

Class I-restricted T-cell responses to a polymorphic peptide in a gene therapy clinical trial for α-1-antitrypsin deficiency.

Calcedo R, Somanathan S, Qin Q, Betts MR, Rech AJ, Vonderheide RH, Mueller C, Flotte TR, Wilson JM.

Proc Natl Acad Sci U S A. 2017 Feb 14;114(7):1655-1659. doi: 10.1073/pnas.1617726114. Epub 2017 Jan 30.

9.

Immune Cytolytic Activity Stratifies Molecular Subsets of Human Pancreatic Cancer.

Balli D, Rech AJ, Stanger BZ, Vonderheide RH.

Clin Cancer Res. 2017 Jun 15;23(12):3129-3138. doi: 10.1158/1078-0432.CCR-16-2128. Epub 2016 Dec 22.

10.

Lack of immunoediting in murine pancreatic cancer reversed with neoantigen.

Evans RA, Diamond MS, Rech AJ, Chao T, Richardson MW, Lin JH, Bajor DL, Byrne KT, Stanger BZ, Riley JL, Markosyan N, Winograd R, Vonderheide RH.

JCI Insight. 2016 Sep 8;1(14). pii: 88328. doi: 10.1172/jci.insight.88328.

11.

Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer.

Twyman-Saint Victor C, Rech AJ, Maity A, Rengan R, Pauken KE, Stelekati E, Benci JL, Xu B, Dada H, Odorizzi PM, Herati RS, Mansfield KD, Patsch D, Amaravadi RK, Schuchter LM, Ishwaran H, Mick R, Pryma DA, Xu X, Feldman MD, Gangadhar TC, Hahn SM, Wherry EJ, Vonderheide RH, Minn AJ.

Nature. 2015 Apr 16;520(7547):373-7. doi: 10.1038/nature14292. Epub 2015 Mar 9.

12.

Dynamic interplay of oncogenes and T cells induces PD-L1 in the tumor microenvironment.

Rech AJ, Vonderheide RH.

Cancer Discov. 2013 Dec;3(12):1330-2. doi: 10.1158/2159-8290.CD-13-0775.

13.

CD25 blockade depletes and selectively reprograms regulatory T cells in concert with immunotherapy in cancer patients.

Rech AJ, Mick R, Martin S, Recio A, Aqui NA, Powell DJ Jr, Colligon TA, Trosko JA, Leinbach LI, Pletcher CH, Tweed CK, DeMichele A, Fox KR, Domchek SM, Riley JL, Vonderheide RH.

Sci Transl Med. 2012 May 16;4(134):134ra62. doi: 10.1126/scitranslmed.3003330.

14.

Homeostasis of peripheral FoxP3(+) CD4 (+) regulatory T cells in patients with early and late stage breast cancer.

Rech AJ, Mick R, Kaplan DE, Chang KM, Domchek SM, Vonderheide RH.

Cancer Immunol Immunother. 2010 Apr;59(4):599-607. doi: 10.1007/s00262-009-0780-x. Epub 2009 Oct 24.

PMID:
19855964
15.

Clinical use of anti-CD25 antibody daclizumab to enhance immune responses to tumor antigen vaccination by targeting regulatory T cells.

Rech AJ, Vonderheide RH.

Ann N Y Acad Sci. 2009 Sep;1174:99-106. doi: 10.1111/j.1749-6632.2009.04939.x. Review.

PMID:
19769742
16.

Collapse of the CD27+ B-cell compartment associated with systemic plasmacytosis in patients with advanced melanoma and other cancers.

Carpenter EL, Mick R, Rech AJ, Beatty GL, Colligon TA, Rosenfeld MR, Kaplan DE, Chang KM, Domchek SM, Kanetsky PA, Fecher LA, Flaherty KT, Schuchter LM, Vonderheide RH.

Clin Cancer Res. 2009 Jul 1;15(13):4277-87. doi: 10.1158/1078-0432.CCR-09-0537. Epub 2009 Jun 23.

Supplemental Content

Support Center